Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amgen Astellas Biopharma to Become a Wholly Owned Amgen Affiliate","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Amgen Data To Be Presented At ESC Congress 2020 Highlighting Repatha\u00ae (evolocumab) Efficacy In High-Risk Patient Populations","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Efficacy Of Repatha\u00ae (Evolocumab) Across High-Risk Patient Populations Reinforced At ACC.21","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data At ESC Congress 2021 Shows Repatha\u00ae Improves Features Of Plaque Stability In Patients With Acute Coronary Syndrome","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Repatha\u00ae (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Announces Results From Two Open Label Extension Studies of Repatha\u00ae (Evolocumab)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen to Present New Data at ESC Congress 2022 Highlighting Up to 8.5 Years of Repatha\u00ae (Evolocumab) Safety and Tolerability Data in High-risk ASCVD Patient Populations","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Amgen Data at ESC 2022 Show Long-term LDL-C Lowering With Repatha\u00ae (Evolocumab) Was Well-tolerated for More Than 8 Years","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen to Present New Repatha\u00ae (evolocumab) and Olpasiran Data at ACC","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Evolocumab

    Menu

    Evolocumab

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    GLOBAL SALES INFORMATION

    MARKET PLACE

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Amgen Inc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Amgen to Present New Repatha® (evolocumab) and Olpasiran Data at ACC

              Details:

              Repatha (evolocumab) inhibits PCSK9 protein and prevents it from binding to the LDL receptor (LDLR), allowing LDLR to recycle back to the liver. By inhibiting the protein, the drug increases the number of LDLRs to clear from the blood, reducing LDL levels.

              Lead Product(s): Evolocumab

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Repatha

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Amgen Inc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              New Amgen Data at ESC 2022 Show Long-term LDL-C Lowering With Repatha® (Evolocumab) Was Well-tolerated for More Than 8 Years

              Details:

              FOURIER is part of Amgen's PROFICIO (Program to Reduce LDL-C and cardiovascular Outcomes Following Inhibition of PCSK9 In different populations) program of clinical studies investigating the impact of Repatha® on LDL-C and CVD across multiple populations.

              Lead Product(s): Evolocumab

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Repatha

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 29, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Amgen Inc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Amgen to Present New Data at ESC Congress 2022 Highlighting Up to 8.5 Years of Repatha® (Evolocumab) Safety and Tolerability Data in High-risk ASCVD Patient Populations

              Details:

              FOURIER-OLE studies are longest trials with PCSK9i to date, with patients receiving Repatha (evolocumab) for a median of 5 years and some patients receiving Repatha continuously for up to 8.5 years across the FOURIER and OLE study period.

              Lead Product(s): Evolocumab

              Therapeutic Area: Genetic Disease Product Name: Repatha

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 22, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Amgen Inc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Amgen Announces Results From Two Open Label Extension Studies of Repatha® (Evolocumab)

              Details:

              Repatha, a human mAB that inhibits proprotein convertase subtilisin/kexin type 9, showed sustained reduction in LDL-C with no new safety findings in Phase 3 FOURIER cardiovascular outcomes trial.

              Lead Product(s): Evolocumab

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Repatha

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 27, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Amgen Inc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              FDA Approves Repatha® (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia

              Details:

              Repatha® (evolocumab) is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) for the treatment of homozygous familial hypercholesterolemia (HoFH) for younger pediatric patients.

              Lead Product(s): Evolocumab

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Repatha

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 24, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Amgen Inc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              New Data At ESC Congress 2021 Shows Repatha® Improves Features Of Plaque Stability In Patients With Acute Coronary Syndrome

              Details:

              New positive phase 3 data for repatha in ACS patients who initiated treatment in the acute setting. Repatha in addition to optimized statin therapy improves features of plaque morphology twice as well as statins alone.

              Lead Product(s): Evolocumab

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Repatha

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 27, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Amgen Inc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Efficacy Of Repatha® (Evolocumab) Across High-Risk Patient Populations Reinforced At ACC.21

              Details:

              The studies provide the body of evidence for treatment in a variety of high-risk patients and contributed to Repatha being approved in more than 75 countries. Notably, Amgen recently passed the milestone of more than one million patients receiving Repatha worldwide.

              Lead Product(s): Evolocumab

              Therapeutic Area: Infections and Infectious Diseases Product Name: Repatha

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 11, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Amgen Inc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              New Amgen Data To Be Presented At ESC Congress 2020 Highlighting Repatha® (evolocumab) Efficacy In High-Risk Patient Populations

              Details:

              Notable abstracts include data from the first randomized controlled Phase 3 study of a PCSK9 inhibitor, Repatha, in pediatric patients with heterozygous familial hypercholesterolemia (HeFH), which will be presented as a late-breaking abstract in an oral presentation.

              Lead Product(s): Evolocumab

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Repatha

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 25, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Astellas Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Amgen Astellas Biopharma to Become a Wholly Owned Amgen Affiliate

              Details:

              Amgen Astellas BioPharma and Astellas have worked on Repatha for familial hypercholesterolemia, BLINCYTO and EVENITY. Under acquisition, Amgen Astellas BioPharma will change its name to Amgen K.K., and simultaneously relocate its Headquarters to Tokyo Midtown.

              Lead Product(s): Evolocumab

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Repatha

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Amgen Inc

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition January 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY